БИБЛИОТЕКА
-
- Фильтр
- Количество записей: 3182
-
- По дате
- По просмотрам
-
Зарубежные материалы
High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
Aims/hypothesis The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes.
Подробнее688
-
Зарубежные материалы
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017
Te International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and IDF predicts that the number of cases of diabetes will rise to 642 million by 2040
Подробнее660
-
Статьи
Алгоритмы специализированной медицинской помощи больным сахарным диабетом (9-й выпуск)
Данное издание содержит восьмой актуализированный выпуск клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.
Подробнее848
-
Зарубежные материалы
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.
Подробнее527
-
Зарубежные материалы
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
Подробнее487
-
Зарубежные материалы
Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial
People with schizophrenia die 10–20 years earlier than the general population, with approximately 75% of deaths resulting from physical illness.1 The twofold increased prevalence of overweight and obesity contributes to this excess mortality.2 Some, but not all, studies suggest that dietary
Подробнее450
-
Зарубежные материалы
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
Подробнее664
-
Зарубежные материалы
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
Подробнее466
-
Зарубежные материалы
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease.
Подробнее574
-
Зарубежные материалы
Cardiorenal Syndrome
The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heartkidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology, the time-frame, and the nature of concomitant cardiac and renal dysfun ...
Подробнее603
-
Зарубежные материалы
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.
Подробнее568
-
Зарубежные материалы
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Подробнее594
-
Зарубежные материалы
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).
Подробнее454
-
Статьи
Особенности почечной патологии у больных сахарным диабетом 2 типа
Сахарный диабет [СД] 2 типа относится к числу наиболее распространенных заболеваний.
Подробнее555
-
Зарубежные материалы
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (HHS Public Access)
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
Подробнее699
- ← Предыдущая
- 1
- ...
- 125
- 126
- 127
- 128 (current)
- 129
- 130
- 131
- ...
- 213
- Следующая →